Background:Total ankle replacement(TAR)is a viable option for the treatment of end-stage ankle arthritis.In China,the INBONE-II implant is the only total ankle prosthesis approved since 2016.The purpose of this study ...Background:Total ankle replacement(TAR)is a viable option for the treatment of end-stage ankle arthritis.In China,the INBONE-II implant is the only total ankle prosthesis approved since 2016.The purpose of this study is to report a large sample of findings for the TAR with INBONE-II prosthesis.Methods:A total of 64 patients with end-stage ankle arthritis,who underwent primary TAR using INBONE-II by the same surgeon from 2016 to 2019,at a single institution were included in this retrospective,single-center study.Clinical data,radiographic findings,survival rate,and complications were recorded and assessed pre-operatively and at the most recent follow-up.Results:A total of 64 patients were available for follow-up at least 2 years after surgery;the mean follow-up duration for clinical outcomes was 37.9 months(24–59 months),and for radiographic findings was 22.8 months(12–59 months).There were significant improvements(P<0.01)in the American Orthopedic Foot and Ankle Society hindfoot scale,the visual analog scale for pain,and the Short Form-36.There were statistically significant differences between pre-operative and post-operative comparisons of the talar tilt angle(TT)and the tibial lateral surface angle(TLS)in the radiographic findings(TT from 4.7±4.3°to 1.3±1.3°,TLS from 80.4±7.7°to 87.4±2.3°,P<0.01).There was no statistically significant difference in improvement of the tibial anterior surface angle(P=0.14).Ten complications(all low grade)were recorded according to the Glazebrook classification system.The survivorship of the prosthesis was 100%(64/64).Conclusion:Patients who underwent TAR with INBONE-II prosthesis demonstrated significant improvements in all measures of pain and function as well as in radiographic findings.High survival and a low incidence of complications were observed in this study.展开更多
基金This study was support by agrant from the Capital's Funds for Health Improvement and Research(No.CFH 2022-2-1122).
文摘Background:Total ankle replacement(TAR)is a viable option for the treatment of end-stage ankle arthritis.In China,the INBONE-II implant is the only total ankle prosthesis approved since 2016.The purpose of this study is to report a large sample of findings for the TAR with INBONE-II prosthesis.Methods:A total of 64 patients with end-stage ankle arthritis,who underwent primary TAR using INBONE-II by the same surgeon from 2016 to 2019,at a single institution were included in this retrospective,single-center study.Clinical data,radiographic findings,survival rate,and complications were recorded and assessed pre-operatively and at the most recent follow-up.Results:A total of 64 patients were available for follow-up at least 2 years after surgery;the mean follow-up duration for clinical outcomes was 37.9 months(24–59 months),and for radiographic findings was 22.8 months(12–59 months).There were significant improvements(P<0.01)in the American Orthopedic Foot and Ankle Society hindfoot scale,the visual analog scale for pain,and the Short Form-36.There were statistically significant differences between pre-operative and post-operative comparisons of the talar tilt angle(TT)and the tibial lateral surface angle(TLS)in the radiographic findings(TT from 4.7±4.3°to 1.3±1.3°,TLS from 80.4±7.7°to 87.4±2.3°,P<0.01).There was no statistically significant difference in improvement of the tibial anterior surface angle(P=0.14).Ten complications(all low grade)were recorded according to the Glazebrook classification system.The survivorship of the prosthesis was 100%(64/64).Conclusion:Patients who underwent TAR with INBONE-II prosthesis demonstrated significant improvements in all measures of pain and function as well as in radiographic findings.High survival and a low incidence of complications were observed in this study.
